Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IV/IM Susceptible infections 1-2 g 8-12 hrly. Pseudomonal lung infections in cystic fibrosis 100-150 mg/kg 8 hrly. Max: 9 g/day. Prophylaxis of surgical infection in patients undergoing prostate surgery 1 g at the induction of anaesth, may repeat upon catheter removal.
Hypersensitivity to ceftazidime or other cephalosporins.
Special Precautions
Patient w/ history of penicillin allergy, seizure disorder. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor renal function. Observe for signs and symptoms of anaphylaxis during 1st dose.
Adverse Reactions
Diarrhoea, nausea, vomiting, abdominal pain, metallic taste; eosinophilia, thrombocytosis; pruritus, rash (maculopapular, erythematous), urticaria, photosensitivity, angioedema, fever; transient increases in serum concentrations of AST, ALT, alkaline phosphatase, LDH, γ-glutamyltransferase, bilirubin, serum creatinine concentrations; local reactions (e.g. phlebitis, pain or inflammation at inj site), candidiasis, vaginitis. Rarely, transient leucopenia, neutropenia thrombocytopenia, agranulocytosis, lymphocytosis.
Potentially Fatal: Anaphylactic reactions, Clostridium difficile-associated diarrhoea and colitis.
Drug Interactions
May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
CIMS Class
ATC Classification
J01DD02 - ceftazidime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on ceftazidime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in